LGT Group Foundation’s Biogen BIIB Stock Holding History

LGT Group Foundation’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-350	Closed	-$75.5K	–	268
2024 Q1	$75.5K	Buy	+350	New	+$82K	﹤0.01%	245

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LGT Group Foundation's BIIB Position: Q2 2024 in Review

LGT Group Foundation sold out of Biogen (BIIB) in Q2 2024, closing a stake of 350 shares — an estimated $75.5K sold.

LGT Group Foundation first reported a position in BIIB in Q1 2024 and held it in 1 quarter. The position peaked at $75.5K in Q1 2024. 943 funds tracked by Wall St. Rank hold BIIB as of Q2 2024.

LGT Group Foundation reported no remaining Biogen position as of Q2 2024 after selling out during the quarter.
LGT Group Foundation sold 350 Biogen shares in Q2 2024, an estimated $75.5K.
LGT Group Foundation first reported a position in Biogen in Q1 2024 and held it in 1 quarter.
LGT Group Foundation's Biogen position peaked at $75.5K in Q1 2024.
943 funds tracked by Wall St. Rank held Biogen as of Q2 2024.

Based on LGT Group Foundation's 13F filing for Q2 2024, filed 7 Aug 2024.